Austedo (deutetrabenazine) Letter of Medical Necessity
Austedo (deutetrabenazine) is FDA-approved for both tardive dyskinesia and Huntington's chorea. It competes directly with Ingrezza in PA review, with payers requiring step-therapy between the two. A complete LMN documents TD diagnosis with AIMS severity, dopamine antagonist exposure history, depression/suicidality screening, and clinical rationale for twice-daily dosing when applicable.
FDA-Approved Indications
- ● tardive dyskinesia (TD) in adults
- ● chorea associated with Huntington's disease
Why Austedo Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Tardive dyskinesia not documented with AIMS score
- 2. Dopamine receptor blocking agent exposure history missing
- 3. Ingrezza (valbenazine) preferred on formulary as once-daily alternative
- 4. Depression or suicidality screening not documented (black box warning)
- 5. CYP2D6 genotype or dose adjustment not addressed for patients on strong CYP2D6 inhibitors
- 6. Quantity limit exceeded
What to Include in a Austedo Letter of Medical Necessity
Document TD or HD chorea diagnosis with AIMS score (TD) or UHDRS chorea score (HD), causative dopamine receptor blocking agent exposure history, PHQ-9 or depression/suicidality screening (required due to black box warning), current concomitant medications (especially strong CYP2D6 inhibitors — requires dose cap), prior VMAT2 inhibitor use if step therapy applies, and rationale for deutetrabenazine — including twice-daily dosing for patients requiring dose titration flexibility.
Key clinical evidence to cite:
- ✓ ARM-TD Phase 3 trial — significant AIMS score improvement vs placebo in TD
- ✓ AIM-TD — dose-response relationship confirmed
- ✓ ARC-HD — chorea improvement in Huntington's disease
- ✓ Improved tolerability vs tetrabenazine due to deuterium substitution reducing peak drug concentration variability
Relevant guidelines:
- 📖 AAN Tardive Syndromes Practice Guideline
- 📖 ASCP 2022 Tardive Dyskinesia Consensus Statement
- 📖 Huntington Study Group HD Treatment Recommendations
Austedo Prior Authorization Criteria
Standard criteria across major US payers for Austedo. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Documented failure or contraindication to formulary alternatives
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Austedo
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Austedo Prior Authorization FAQ
Why was my Austedo prior authorization denied?
The most common denial reasons for Austedo are: Tardive dyskinesia not documented with AIMS score; Dopamine receptor blocking agent exposure history missing; Ingrezza (valbenazine) preferred on formulary as once-daily alternative; Depression or suicidality screening not documented (black box warning); CYP2D6 genotype or dose adjustment not addressed for patients on strong CYP2D6 inhibitors; Quantity limit exceeded.
What should a Austedo Letter of Medical Necessity include?
Document TD or HD chorea diagnosis with AIMS score (TD) or UHDRS chorea score (HD), causative dopamine receptor blocking agent exposure history, PHQ-9 or depression/suicidality screening (required due to black box warning), current concomitant medications (especially strong CYP2D6 inhibitors — requires dose cap), prior VMAT2 inhibitor use if step therapy applies, and rationale for deutetrabenazine — including twice-daily dosing for patients requiring dose titration flexibility.
Which payers cover Austedo?
Austedo is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Humana, Medicare Part D, though formulary tier and prior authorization criteria vary.